Combination treatment for primary membranous nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have primary membranous nephropathy, confirmed by a kidney biopsy.
- You have significant protein in your urine (more than 5 grams per day) and low blood protein levels (albumin below 30 g/L), despite at least 3 months of standard blood pressure medication.
- Your kidney function is at least moderately preserved (eGFR at least 40).
- Your blood pressure is well controlled (140/90 or lower) for the last 3 months.
- You have not taken certain immune-suppressing drugs like rituximab, cyclosporine, or steroids within the past 3 to 12 months.
- You do not have an active infection such as tuberculosis, hepatitis B or C, or HIV.
- You are not pregnant or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
This trial tests if an artificial intelligence tool can help doctors decide the best dose and timing of rituximab for people with a kidney condition called membranous nephropathy. It aims to improve treatment results and reduce side effects.
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
This study looks at how rituximab affects immune cells in people with a type of kidney disease called membranous nephropathy. By studying blood samples, the researchers hope to understand why some people respond better to treatment, which could help guide future care.
This Phase 3 trial compares different immune-suppressing medicines for idiopathic membranous nephropathy (a kidney disease caused by the immune system). It may help reduce heavy protein leakage in the urine and improve disease control in people who fit specific prior-treatment and lab requirements.
This trial tests a new drug called B007 for people with primary membranous nephropathy, a kidney condition. It aims to see if B007 can help reduce protein in the urine and protect kidney function.
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.